Literature DB >> 1399234

Diffuse adenomatoid tumor of the uterus with a serosal papillary cystic component.

E G Livingston1, M S Guis, M L Pearl, J L Stern, R J Brescia.   

Abstract

A 39-year-old woman undergoing immunosuppressive therapy following kidney transplantation for systemic lupus erythematosus presented with a uterine adenomatoid tumor that diffusely infiltrated the entire myometrium and contained a serosal papillary cystic component that resembled a cystic mesothelioma. This is the first reported case of an adenomatoid tumor showing both of these features. Although adenomatoid tumors are considered benign, the patient may be at risk for recurrence of the papillary cystic component (which is known to recur in 50% of cases) if this tumor reflects an inability to limit neoplastic processes.

Entities:  

Mesh:

Year:  1992        PMID: 1399234     DOI: 10.1097/00004347-199210000-00007

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  3 in total

1.  Adenomatoid tumors of the female and male genital tract. A comparative clinicopathologic and immunohistochemical analysis of 47 cases emphasizing their site-specific morphologic diversity.

Authors:  David L Wachter; Peter H Wünsch; Arndt Hartmann; Abbas Agaimy
Journal:  Virchows Arch       Date:  2011-02-20       Impact factor: 4.064

Review 2.  Adenomatoid tumours of the gastrointestinal tract - a case-series and review of the literature.

Authors:  Erika Hissong; Rondell P Graham; Kwun Wah Wen; Lindsay Alpert; Jiaqi Shi; Laura W Lamps
Journal:  Histopathology       Date:  2021-10-07       Impact factor: 7.778

3.  Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.

Authors:  Benjamin Goode; Nancy M Joseph; Meredith Stevers; Jessica Van Ziffle; Courtney Onodera; Eric Talevich; James P Grenert; Iwei Yeh; Boris C Bastian; Joanna J Phillips; Karuna Garg; Joseph T Rabban; Charles Zaloudek; David A Solomon
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.